JP2023533807A5 - - Google Patents
Info
- Publication number
- JP2023533807A5 JP2023533807A5 JP2023502631A JP2023502631A JP2023533807A5 JP 2023533807 A5 JP2023533807 A5 JP 2023533807A5 JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023533807 A5 JP2023533807 A5 JP 2023533807A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridine
- dihydro
- piperazine
- isoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/101904 | 2020-07-14 | ||
| CN2020101904 | 2020-07-14 | ||
| CNPCT/CN2021/094138 | 2021-05-17 | ||
| CN2021094138 | 2021-05-17 | ||
| PCT/EP2021/069294 WO2022013136A1 (en) | 2020-07-14 | 2021-07-12 | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533807A JP2023533807A (ja) | 2023-08-04 |
| JP2023533807A5 true JP2023533807A5 (enExample) | 2024-07-22 |
Family
ID=77126791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502631A Ceased JP2023533807A (ja) | 2020-07-14 | 2021-07-12 | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240317735A1 (enExample) |
| EP (1) | EP4182032A1 (enExample) |
| JP (1) | JP2023533807A (enExample) |
| CN (1) | CN115835910A (enExample) |
| TW (1) | TW202216711A (enExample) |
| WO (1) | WO2022013136A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186083A1 (en) * | 2020-08-14 | 2022-02-17 | Remy LUTHRINGER | Condensed azacycles as sigma ligand compounds and uses thereof |
| AU2022351495A1 (en) * | 2021-09-24 | 2024-02-01 | F. Hoffmann-La Roche Ag | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
| CN120230100B (zh) * | 2025-05-30 | 2025-09-05 | 中国药科大学 | 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013032290A (ja) * | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| CR20190119A (es) * | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| WO2018218197A2 (en) * | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| BR112020011984A2 (pt) * | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| KR20210018818A (ko) | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| SG11202110401WA (en) * | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
-
2021
- 2021-07-12 WO PCT/EP2021/069294 patent/WO2022013136A1/en not_active Ceased
- 2021-07-12 US US18/016,289 patent/US20240317735A1/en active Pending
- 2021-07-12 JP JP2023502631A patent/JP2023533807A/ja not_active Ceased
- 2021-07-12 EP EP21748533.3A patent/EP4182032A1/en active Pending
- 2021-07-12 CN CN202180049160.3A patent/CN115835910A/zh active Pending
- 2021-07-13 TW TW110125634A patent/TW202216711A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533807A5 (enExample) | ||
| US12331056B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| JP2024502433A5 (enExample) | ||
| EP3630770B1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| JP2022504936A5 (enExample) | ||
| JP2021527041A5 (enExample) | ||
| JP2023549341A (ja) | Ｂｒｍ標的化化合物及び関連する使用方法 | |
| JP2022543689A (ja) | Ｓｈｐ２阻害剤 | |
| JP2022527588A5 (enExample) | ||
| RU2018133279A (ru) | Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB) | |
| JP2023539663A (ja) | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 | |
| JP2014506929A5 (enExample) | ||
| IL256324A (en) | 1, 4-substituted piperidine derivatives | |
| JP2017524702A (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| CA3098291A1 (en) | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease | |
| JP2024540912A (ja) | 癌の治療における使用のためのヘテロ環式化合物 | |
| JP2022508523A5 (enExample) | ||
| CN118488947A (zh) | 稠环取代的六元杂环化合物及其制法和用途 | |
| JP2024534567A5 (enExample) | ||
| TH2401004994A (th) | อิมิดาโซลมาโครไซเคิลสำหรับการบำบัดของโรคภูมิต้านต่อตนเอง | |
| RU2020142969A (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ | |
| RU2024111196A (ru) | Соединения пиразоло[3,4-b]пиридина для лечения аутоиммунного заболевания | |
| RU2025127920A (ru) | Соединения пиридазина, их получение и пути их терапевтического применения | |
| RU2025108617A (ru) | Гетероциклические производные в качестве ингибиторов янус-киназы | |
| NZ768960A (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |